US to be canvassed on whether FDA performance criteria are "appropriate"
This article was originally published in Clinica
The US FDA's device centre has scheduled a stakeholder meeting for May 22 to solicit public comment on whether it should revise two user-fee-related performance goals for fiscal year 2007. The two performance goals are considered to be the most ambitious commitments made by the FDA in 2002, when it was trying to win industry's support for device user fees. One pledges that the device review staff would complete work on 50% of the premarket approval applications or PMAs within 180 days. The other calls for processing 80% of all 510(k)s within 90 days.
You may also be interested in...
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.
Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.